Back to Research Home
DHRDanaher Corporation
Health Care · Life Sciences Tools & Services · Large
$230.50+0.33%
As of 23 Oct 2026Mkt cap $148B
Stage 13
AVOID
Fundamentals
39.9/75
Technical
6.5/15
Independent
46.4/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +3.0%
- 3M
- +17.3%
- 6M
- +30.0%
- 1Y
- +5.7%
Financials & valuation
Cached filing evidence · as of 2026-10-21
Valuation
- P/E
- 37.7xHist median 40.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 28.8x
- FCF yield
- 3.5%
Quality
- ROIC
- 6.0%
- Operating margin
- 20.4%
- FCF margin
- 21.4%
- Current ratio
- 1.9x
Growth
- Revenue growth
- +2.9%Latest FY YoY
- Revenue CAGR
- −0.2%
- EPS CAGR
- −12.5%
- FCF CAGR
- −7.3%
Capital
- Share-count trend
- −1.8%3Y annualised
- Net debt
- $15.1B2.4x OCF
Annual trend
- CAGR 2021–2025
- −0.2%
- Latest · 2025
- $25B
- YoY
- +2.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-27
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-21
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded